Want to see CTNM full AI Analyst Report?
Top Page
Contineum Therapeutics, Inc. Class A
(NASDAQ:CTNM)
Select Model
Select Model
Rating:54Neutral
Price Target:
$16.00
▲(13.80% Upside)
Action:Reiterated
Date:07/31/26
The score is held back primarily by weak financial performance (no TTM revenue, large losses, and significant ongoing cash burn), partially offset by a comparatively strong, low-leverage balance sheet. Technicals are supportive with the stock above major moving averages, and corporate events are positive due to encouraging PIPE-791 clinical readouts and strategy/runway messaging. Valuation remains constrained by negative earnings (negative P/E) and no dividend data.
Positive Factors
Balance sheet strength
Contineum’s low leverage and sizable equity base provide durable financial flexibility to fund multi-year R&D programs. A strong balance sheet supports negotiating power with partners, preserves optionality for milestone-driven investments, and lowers near-term solvency risk while clinical readouts progress.
Negative Factors
No recurring revenue / persistent losses
Contineum remains a pre-revenue, development-stage biotech with sizable operating losses. Persistent lack of product revenue means long-term sustainability depends on successful clinical outcomes or deal-generated milestone revenue; absent those, financing and dilution risk persist as structural threats.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Contineum’s low leverage and sizable equity base provide durable financial flexibility to fund multi-year R&D programs. A strong balance sheet supports negotiating power with partners, preserves optionality for milestone-driven investments, and lowers near-term solvency risk while clinical readouts progress.
Read all positive factors
Contineum Therapeutics, Inc. Class A (CTNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$579.11M
Dividend YieldN/A
Average Volume (3M)170.88K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue GrowthN/A
EPS Growth21.01%
CountryUS
Employees51
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.73
Shares Outstanding32,723,877
10 Day Avg. Volume105,448
30 Day Avg. Volume170,880
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.21
Price to Sales (P/S)0.00
P/FCF Ratio-5.70
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$23.40Price Target Upside66.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.65
Revenue Forecast (FY)$8.26M
Contineum Therapeutics, Inc. Class A Business Overview & Revenue Model
Company Description
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIP...
How the Company Makes Money
As a clinical-stage biotechnology company, Contineum Therapeutics does not typically generate recurring revenue from product sales unless it has approved and commercialized drugs; information confirming any marketed/approved products and related s...
Contineum Therapeutics, Inc. Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 50.00M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -258.00K | 50.00M | 0.00 | 0.00 |
| EBITDA | -66.00M | -67.74M | -42.00M | 23.57M | -23.54M | -28.34M |
| Net Income | -57.56M | -59.98M | -42.26M | 22.72M | -24.25M | -29.00M |
Balance Sheet | ||||||
| Total Assets | 250.37M | 276.64M | 212.85M | 130.39M | 50.64M | 70.52M |
| Cash, Cash Equivalents and Short-Term Investments | 236.55M | 262.90M | 204.76M | 125.19M | 47.24M | 69.00M |
| Total Debt | 6.57M | 8.25M | 6.26M | 193.19M | 5.85M | 4.91M |
| Total Liabilities | 10.71M | 15.65M | 14.78M | 198.32M | 11.37M | 8.93M |
| Stockholders Equity | 239.66M | 260.99M | 198.07M | -67.94M | 39.27M | 61.59M |
Cash Flow | ||||||
| Free Cash Flow | -53.46M | -55.54M | -33.36M | 18.93M | -20.24M | -26.43M |
| Operating Cash Flow | -53.01M | -55.31M | -32.84M | 19.35M | -20.12M | -26.27M |
| Investing Cash Flow | -66.97M | -3.71M | -69.74M | -65.57M | 22.30M | -64.97M |
| Financing Cash Flow | 113.90M | 112.69M | 109.00M | 56.18M | -1.24M | 79.84M |
Contineum Therapeutics, Inc. Class A Technical Analysis
Positive
14.06
Price Trends
13.66
Positive
13.45
Positive
12.90
Positive
Market Momentum
0.30
Negative
59.30
Neutral
78.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTNM, the sentiment is Positive. The current price of 14.06 is below the 20-day moving average (MA) of 14.63, above the 50-day MA of 13.66, and above the 200-day MA of 12.90, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 59.30 is Neutral, neither overbought nor oversold. The STOCH value of 78.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTNM.
Contineum Therapeutics, Inc. Class A Risk Analysis
Contineum Therapeutics, Inc. Class A disclosed 78 risk factors in its most recent earnings report. Contineum Therapeutics, Inc. Class A reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Contineum Therapeutics, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $579.11M | -8.95 | -24.73% | ― | ― | 21.01% | |
54 Neutral | $267.20M | -3.53 | -0.11% | ― | ― | 40.79% | |
52 Neutral | $1.06B | -17.60 | -73.23% | ― | ― | -42.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $119.91M | -1.36 | -29.34% | ― | ― | -32.34% | |
46 Neutral | $222.96M | -1.66 | -59.27% | ― | -100.00% | -62.96% | |
45 Neutral | $19.70M | -1.32 | -64.17% | ― | -100.00% | 94.65% |
* Healthcare Sector Average
CTNM
Contineum Therapeutics, Inc. Class A
15.93
10.13
174.66%
TVRD
Tvardi Therapeutics
2.02
-24.32
-92.33%
CAPR
Capricor Therapeutics
4.20
-3.48
-45.31%
DRTS
Alpha Tau Medical Ltd
11.92
8.90
294.70%
IMRX
Immuneering
4.17
0.74
21.57%
ENGN
enGene Holdings
1.77
-2.05
-53.66%
Contineum Therapeutics, Inc. Class A Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Contineum Therapeutics Updates Strategy, Highlights PIPE-791 Leadership
Positive
Jul 13, 2026
On July 13, 2026, Contineum Therapeutics updated its corporate presentation to highlight strategic and business developments, notably emphasizing PIPE-791 as its lead, brain-penetrant LPAR1 antagonist for idiopathic pulmonary fibrosis and chronic ...
Executive/Board ChangesShareholder Meetings
Contineum Stockholders Hold 2026 Virtual Annual Meeting
Positive
Jun 26, 2026
On June 26, 2026, Contineum Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders virtually, with 32,723,877 shares of Class A common stock eligible to vote as of the April 27, 2026 record date. Stockholders elected three Class II direct...
Business Operations and StrategyProduct-Related Announcements
Contineum Therapeutics Reports Positive Phase 1b Chronic Pain Data
Positive
Apr 30, 2026
On April 30, 2026, Contineum Therapeutics reported positive topline results from an exploratory Phase 1b trial of its non-opioid candidate PIPE-791 in patients with chronic osteoarthritis pain and chronic low back pain. PIPE-791, given orally at 1...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.